Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-05
2011-04-05
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S361100
Reexamination Certificate
active
07919518
ABSTRACT:
The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.
REFERENCES:
patent: 0 382 276 (1995-08-01), None
patent: 0 510 748 (1996-03-01), None
patent: 1 185 528 (2002-03-01), None
patent: 1 188 438 (2002-03-01), None
patent: 1 199 074 (2002-04-01), None
patent: 1 005 332 (2003-10-01), None
patent: 1 369 119 (2003-12-01), None
patent: 1 458 687 (2004-09-01), None
patent: 1 675 862 (2006-07-01), None
patent: 1 819 341 (2007-08-01), None
patent: 1 827 447 (2007-09-01), None
patent: 1 869 055 (2007-12-01), None
patent: 1 869 056 (2007-12-01), None
patent: WO 99/04770 (1999-02-01), None
patent: WO 99/04770 (1999-02-01), None
patent: WO 00/78757 (2000-12-01), None
patent: WO 03/047516 (2003-06-01), None
patent: WO 2005/033115 (2005-04-01), None
patent: WO 2006/053227 (2006-05-01), None
patent: WO 2006/060194 (2006-06-01), None
patent: WO 2006/107257 (2006-10-01), None
patent: WO 2006/107258 (2006-10-01), None
Barrett J. Rollins, “Chemokines”, Blood, vol. 90, No. 3, Aug. 1, 1997, 23 Pages.
Marco Baggiolini, “Chemokines and Leukocyte Traffic”. Nature, vol. 392. Apr. 9, 1998, pp. 565-568.
Craig Gerard et al., “Chemokines and Disease”, Nature Immunology, vol. 2, No. 2, Feb. 2001, pp. 108-115.
Surendran Mahalingam et al., “Chemokines and Viruses: Friends or Foes?”, Trends in Microbiology, vol. 11, No. 8, Aug. 2003, pp. 383-391.
Nestor E. Rulli et al., “Ross River Virus: molecular and Cellular Aspects of Disease Pathogenesis”, Pharmacology and Therapeutics, vol. 107, 2005, pp. 329-342.
Toshihiro Nanki et al., “Migration of CX3CR1-Positive T Cells Producing Type 1 Cytokines and Cytotoxic Molecules into the Synovium of Patients with Rheumatoid Arthritis”, Arthritis and Rheumatism, vol. 46, No. 11, Nov. 2002, pp. 2878-2883.
Stephan Segerer et al., “Expression of the Fractalkine Receptor (CX3CR1) in Human Kidney Diseases”, Kidney International, vol. 62, 2002, pp. 488-495.
Miquel Sans et al., “Enhanced Recruitment of CX3CR1+ T Cells by Mucosal Endothelial Cell-Derived Fractalikine in Inflammatory Bowel Disease”, Gastroenterology, vol. 132, No. 1, 2007, pp. 139-153.
Ping Liu et al., “Cross Talk Among Smad, MAPK, and Integrin Signaling Pathways Enhances Adventitial Fibroblast Functions Activated by Transforming Growth Factor21 and Inhibited by Gax”, Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, Jan. 10, 2008, 23 Pages.
David H. McDermott et al., “Chemokine Receptor Mutant CX3CR1-M280 has Impaired Adhesive Function and Correlates with Protection from Cardiovascular Disease in Humans”, The Journal of Clinical Investigation, vol. 111, No. 8, Apr. 2003, pp. 1241-1250.
Alexander Niessner et al., “Wound Healing and Inflammation/Infection: Fractalkine Receptor Polymorphisms V2491 and T280M as Genetic Risk Factors for Restenosis”, Thrombosis and Haemostasis, vol. 94, 2005, pp. 1251-1256.
Dr. John Koo, “Population-Based Epidemiologic Study of Psoriasis with Emphasis on Quality of Life Assessment”, Psychodermatology, vol. 14, No. 3, Jul. 1996, pp. 485-496.
Dr. Michael P. Schoen et al., “Medical Progress: Psoriasis”, The New England Journal of Medicine, vol. 352, No. 18, May 5, 2005, pp. 1899-1912.
Marina Sironi et al., “A Small Synthetic Molecule Capable of Preferentially Inhibiting the Production of the CC Chemokine Monocyte Chemotactic Protein-1”, European Cytokine Network, vol. 10, No. 3, Sep. 1999, pp. 437-441.
U.S. Appl. No. 12/865,923, filed Aug. 3, 2010, Guglielmotti, et al.
U.S. Appl. No. 12/865,792, filed Aug. 2, 2010, Guglielmotti, et al.
U.S. Appl. No. 12/866,814, filed Aug. 9, 2010, Guglielmotti, et al.
Cazzolla Nicola
Furlotti Guido
Garofalo Barbara
Guglielmotti Angelo
Mangano Giorgina
Anderson Rebecca L
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Shterengarts Samantha L
LandOfFree
1-benzyl-3-hydroxymethylindazole derivatives and use thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-benzyl-3-hydroxymethylindazole derivatives and use thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-benzyl-3-hydroxymethylindazole derivatives and use thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647665